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HIGHLIGHTS 
 Kidney transplantation is now universally performed in high and low 
Tuberculosis endemic countries. 
 Tuberculosis is an important infectious disease cause of morbidity and death 
in transplant recipients.  
 Tuberculosis can also cause loss of kidney allograft   
 Screening of both donor and recipient for latent TB infection (LTBI) pre-












  A high degree of clinical awareness of the possibility of active TB disease or  
LTBI is required for early diagnosis and treatment. 
 
Abstract 
Background: Tuberculosis (TB) continues to be the commonest infectious disease 
cause of death worldwide. Tuberculosis is an important infectious disease cause of 
morbidity and death in renal transplant recipients. Tuberculosis can also cause loss 
of kidney allograft   
Objectives: The purpose of this viewpoint is to highlight the issues related to 
prevention, diagnosis and treatment of tuberculosis in renal transplant recipients. 
Methods: The PubMed database was searched for publications and guidelines on 
diagnosis and management of LTBI in renal transplantation. Publications on renal 
allograft recipients with LTBI and TB in post-operative period were also analysed. 
Specialist Society guidelines were also used. 
Findings: Tuberculosis is one of the most important infectious diseases related 
cause of morbidity and death in transplant recipients. LTBI in allograft recipients 
continues to be a clinical management problem. It can occur either from donor 
kidney or from endogenous reactivation of latent tuberculosis infection or acquiring 
new Mycobacterium tuberculosis infection. Tuberculosis can also cause loss of 
kidney allograft.   
Conclusions: Kidney transplantation is now universally performed in high and low 
Tuberculosis endemic countries. A high index of awareness of the possibility of TB 
disease or LTBI is required prior to renal transplant aligned to reduce renal allograft 
damage, morbidity and death due to tuberculous. WHO Management 
recommendations for LTBI screening and treatment should be followed. 
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Tuberculosis (TB) is the commonest infectious disease cause of death worldwide 
(WHO 2018a). An estimated 1.3 million people died of tuberculosis in 2017. Recent 
modelling re-calculations indicate that there are 1.7 billion people worldwide with 
latent Mycobacterium tuberculosis infection (LTBI) (Houben & Dodd 2016). Latent 
tuberculosis infection is defined by the World Health Organisation (WHO) as ‘a state 
of persistent immune response to stimulation by Mycobacterium tuberculosis (M.tb) 
antigens with no evidence of clinically manifest active TB disease’ (WHO, 2018b). 
Upto 10% of people with LTBI will progress to developing active TB disease during 
their lifetime.   The highest risk for developing TB disease occurs when a range of 
risk factors for re-activation LTBI are when conditions of immunosuppression are 
present such as diabetes, malnutrition, HIV, and prescription of biologics and 
immunosuppressive agents including anti-rejection therapies in transplant patients 
(Hasan et al, 2018).  
The incidence of active TB disease among renal transplant recipients is much higher 
than in general population (Lopez et al, 2010) and causes much morbidity and death 
occurring in these patients (Anand et al, 2017). TB is also responsible for loss of the 
renal allograft (transplanted kidney) in approximately one third of cases. Most of the 
TB cases in renal transplant recipients are due to re-activation of LTBI in the 
recipient or from donor kidney (Viana et al, 2018; Abad et al, 2018a; Abad et al, 
2018b).  TB can also occur due to increased susceptibility to acquiring new M.tb 
infection which rapidly progresses to miliary TB because of immunosuppressive 
therapy. Living donors who were born and lived in high TB endemic countries and 
migrated to low TB endemic areas may have higher rates of LTBI. The diagnosis and 












quite challenging since the presentation is cryptic with non-specific symptoms and 
signs, and the diagnosis can easily be missed unless there is a high degree of 
awareness of the possibility of TB. The clinical presentation of TB occurring in 
transplant recipients is said to differ from that in the general population and an 
increased frequency of extrapulmonary TB is seen (Viana et al, 2018; Abad et al, 
2018a; Abad et al, 2018b). 
Screening and Diagnosis of LTBI 
Kidney transplantation is now universally performed in high and low TB endemic 
countries. All renal transplant recipients and their donors should undergo screening 
for LTBI and active TB disease prior to transplant.   There is no gold standard test for 
diagnosing LTBI accurately. WHO recommends three tests for screening for LTBI: 
Tuberculin skin test (TST) and two interferon gamma release assays (IGRAs) 
namely, QuantiFERON®-TB (QFT) Gold In-Tube and T-SPOT® T (WHO 2018b).  
The TST may be unreliable in patients with advanced chronic kidney disease and in 
those on immunosuppressive agents (Guirao-Arrabal  et al 2018). IGRAs are more 
specific to M.tb antigens and offer high specificity in detecting LTBI in 
immunosuppressed patients (Pai et al, 2014; Guirao-Arrabal  et al, 2018). There is a 
scanty data on the sensitivities and specificities of IGRAs and TST in screening for 
LBI in renal transplant recipients. Based on extrapolating data from studies of 
haemodialysis patients, there are likely to be more false positive, false negative and 
indeterminate results of IGRAs in transplant recipients (Schluger and Burzynski, 
2010). A systematic review and meta-analysis assessed the use of the TST and 
IGRAs (QFT and T-SPOT) in different organ transplantations including liver, renal 
and haemopoetic stem cell (Rahimifard et al, 2018). A higher rate of LTBI was found 












transplantation, especially when IGRA tests were used compare to the TST. Thus 
IGRAs (both QFT and T-SPOT) have been shown to be more sensitive than the TST 
for the diagnosis of LTBI in patients requiring renal transplantation. Furthermore, 
post-transplant TB was more common in renal recipients than in liver transplant 
patients although many variables might have influenced this. In low resource 
settings, TST continues to be used for diagnosing LTBI.  
A diagnostic approach for detection of active and latent tuberculosis has been 
outlined by Demir and Sever, 2017.  Clinical workup of donors and transplant 
recipients to screen for LTBI and active TB  is shown in Fig 1. The TBNET 
consensus group has summarized pathogenesis of LTBI in post-transplant patients 
(Bumbacea et al, 2012). A modification of the pathogenetic mechanisms is depicted 
in Fig 2. Fig 2A depicts the normal allograft transplantation, where neither the donor 
nor the recipient has TB infection. The post-transplant period is uneventful with the 
recipient having a normal post-operative period. Fig 2B depicts the donor kidney 
being infected by M.tb bacilli, which has gone unrecognized pre-transplant 
evaluation of the donor. The M.tb bacilli remain dormant within the transplant kidney 
for months to years. Due to immunosuppressive therapy, there is reactivation of LTBI 
to active TB disease. Fig 2C describes the LTBI in recipient that has gone 
undiagnosed during pre-transplant evaluation, which either continues to persist as 
LTBI or may undergo endogenous reactivation in the post-transplant period. Fig 2D 
depicts a scenario where both the donor and the recipient have been free from 
disease. Post-transplant period also has been uneventful until when the recipient 
gets exposed to M.tb bacilli and develops denovo LTBI. 
Fig 3 illustrates a 44 year old male, who developed derived endogenous reactivation 












undergone a right open nephrectomy for non-functioning right kidney (Fig 3A, 3B). At 
the time of right nephrectomy, he had a normal functioning solitary left kidney. Three 
years later, he developed pelvi-ureteric junction stricture and mid ureteric stricture of 
the solitary left kidney and active TB was diagnosed. Anti-TB treatment and 
percutaneous nephrostomy did not prevent further deterioration of the renal function 
(Fig 3C). A left open nephrectomy was done and was on maintenance haemodialysis 
for 24 months. A live related renal transplantation was subsequently done 2 years 
later (Fig 3D). Four years after the transplant, there was a mild and gradual 
worsening of the renal biochemical parameters, though he was totally asymptomatic. 
In view of mildly rising serum creatinine levels, per cutaneous biopsy from the renal 
allograft was performed, which showed evidence of epithelioid granuloma with 
Langhans giant cells in the graft kidney, suggestive of TB in the renal allograft (Fig 
3E). Patient had a symptomatic and biochemical improvement after initiation of anti-
TB treatment treatment. 
Various meta-analyses and subsequent guidelines recommend that all renal 
transplant candidates should be routinely screened for LTBI (Stagg et al, 2014). This 
should be done prior to transplant wherever practicable. British Thoracic Society 
guidelines suggest screening for LTBI where tuberculosis incidence rates are high or 
in patients with risk factors for developing tuberculosis in low incidence areas 
(Milburn et al British Thoracic Society Guidelines, 2010). Similarly those with 
epidemiologic risk factors such as history of TB in the past, previous rejection 
episodes, high-dose corticosteroids, diabetes mellitus and those living in endemic 
areas need to be evaluated with chest radiography and other screening tests as part 












In low TB endemic countries, LTBI screening is recommended for population 
subgroups with a high prevalence of TB or those with a high likelihood of progression 
from LTBI to active disease. These include close contacts of patients with active 
tuberculosis, recently arrived foreign-born persons, drug users, incarcerated 
persons, and homeless individuals and were advised screening for LTBI (Horsburgh, 
2004).  Chest X-ray, detailed background history of previous exposure to patients 
with TB and risk factor assessment for travel or migration from endemic areas was 
the most frequent recommendation for LTBI screening in immunosuppressed 
individuals and those undergoing Solid Organ Transplant (SOT). (Hasan et al, 2018). 
Kowada recommends an active TB screening with IGRA for all renal allograft 
recipients with individualized risk assessment of each of the patients during LTBI 
treatment (Kowada, 2018). Those patients are recommended to initiate anti-TB 
treatment while they were on waiting list, aiming at a complete treatment schedule 
prior to transplantation. Meanwhile, if there is a need to undergo transplantation, it’s 
worthwhile to temporarily stop the drug intake and recommence the treatment 
schedule to completion once patients were clinically stable.  
 
Treatment of LTBI in donor and recipient 
As tuberculosis could directly affect the allograft function, it is extremely important to 
take utmost efforts to prevent transmission of TB infection in such select subgroup of 
patients. Every effort must be made to diagnose and treat LTBI and active 
tuberculosis in both live donor and recipient before transplantation. Treatment of 
LTBI should follow WHO 2018 guidelines (WHO, 2018b). 
The Consensus Statement from the Spanish Group for the Study of Infectious 












SOT recipients (Aguado et al, 2009). The WHO, 2018 guidelines outline the following 
treatment options for LTBI (WHO, 2018b).  
 Isoniazid monotherapy for 6 months is recommended for treatment of LTBI in both 
adults and children in countries with high and low TB incidence.  
 Rifampicin plus Isoniazid daily for 3 months should be offered as an alternative to 
6 months of isoniazid monotherapy as preventive treatment for children and 
adolescents aged < 15 years in countries with a high TB incidence.  
 Rifapentine and Isoniazid weekly for 3 months may be offered as an alternative to 
6 months of Isoniazid monotherapy as preventive treatment for both adults and 
children in countries with a high TB incidence.  
 The following options are recommended for treatment of LTBI in countries with a 
low TB incidence as alternatives to 6 months of isoniazid monotherapy: 9 months of 
isoniazid, or a 3-month regimen of weekly rifapentine plus isoniazid, or 3–4 months 
of isoniazid plus rifampicin, or 3–4 months of rifampicin alone.  
Patients may find completing the long course of LTBI treatment difficult due to 
adverse effects and the interactions with immunosuppressive drugs and hence 
shorter courses of treatment are recommended.  There is a need for well-designed 
prospective controlled cohort trials of short course LTBI treatment regimens in 
transplant recipients, which should also assess their efficacy, safety, hepatotoxicity 
and adherence to treatment.   
 
Treatment of active TB 
Treatment of drug-sensitive and drug resistant active TB disease in renal transplant 
recipients should follow WHO treatment guidelines (WHO, 2017; WHO, 2018c). 












transplantation remains a challenging task. Hepatotoxicity is  a serious dose limiting 
side effects of both Isoniazid and Rifampicin and this risk is further accentuated in 
patients with pre-existing liver disease and alcoholics. Peripheral neuropathy caused 
by Isoniazid can be prevented by co-administration of pyridoxine. Rifampicin 
interferes with the efficacy of many drugs by interfering with their metabolism. It may 
not be an ideal choice for patients taking oral contraceptives or HIV-infected 
individuals on protease inhibitors or non-nucleoside reverse- transcriptase inhibitors.     
Rifabutin has fewer pharmacologic interactions with antiretroviral agents than 
Rifampicin and can be used in combination with Isoniazid for the treatment of latent 
tuberculosis infection (Matteelli, 1999). Adherence to one specific standardized 
regime, completion of the recommended duration of the regime and a close 
monitoring and early identification of the adverse effects of the drugs would greatly 
enhance the effectiveness of treatment against LTBI. In order to achieve this, each 
transplant centre should design their individual protocol as per the evidence based 
guidelines that would enable a national audit programme be performed to improve 
the quality of health care for this subset LTBI patients (Maynard Smith, 2014). 
Proactive TB screening with IGRA with individualized risk assessment of each of the 
patients and monitoring the drug toxicity during LTBI treatment is to be 
recommended for all renal allograft recipients.  
 
Conclusions 
Renal transplantation is now widely available globally. TB is a serious complication in 
renal transplant recipients and causes much morbidity and mortality. Due to 
immunosuppression, transplant recipients are at a higher risk of re-activating LTBI 












are available and are consistent in recommending that all donors and recipients are 
routinely screened for LTBI and active TB disease prior to transplant whenever 
possible.    A high degree of awareness of the possibility of TB is required in all renal 
transplant patients so that it can be diagnosed and treated early, reducing the risk of 
loss of allograft. 
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Clinical workup of donors and transplant recipients to screen  
for LTBI and active TB   
HISTORY: 
 Contact with patient with active pulmonary TB 
 Previous TB treatment 
 
SYMPTOMS: 
 Chronic cough, night sweats, weight loss, anorexia 
 
FULL CLINICAL EXAMINATION: 
 Examine for active pulmonary TB  
 Exclude extra pulmonary TB   
 
INVESTIGATIONS: 
 Full Blood Count and differential 
 C-Reactive protein (CRP)    
 Renal and liver function Tests 
 Microscopy (for acid fast bacilli) and culture for M.tb (Sputum 
and early morning urine samples) 
 Histology of biopsy or aspirates (acid fast bacilli and granuloma) 
 GeneXpert MTB/Rif Assay (on sputum, urine or biopsy) 
 
TESTS FOR LTBI: 
 Tuberculin skin test (TST) 
 IGRA test (either TSPOT.TB or QuantiFERON) 
 
IMAGING: 
 Chest X-ray 
 Renal ultrasound 
 MRI or CT scan (where indicated) 















FIG 2 :  Pathogenetic mechanisms of LTBI and active TB occurrence in renal 
allograft recipients 
 
FIG 3 : Imaging and histological features of a case of endogenous reactivation of 
LTBI progressing to active TB disease. 
              FIG 3A. Intravenous urogram and FIG 3B ultrasonography showing normal   
              functioning solitary left kidney  
              FIG 3C. Intravenous urogram showing hydronephrosis and nephrostomy of  
              the left kidney (three years later) 
              FIG 3D. MRI showing transplanted kidney (allograft)  












              (Upper panel: Epithelioid granulmas with Langhans Giant cells) 
              (Lower left: Granulomas with caseous necrosis) 
              (Lower right:  
 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
